AI medtech platform and glucometer enabling people to manage their own diabetes

  • $2,014,938Amount raised
  • $1,000Minimum
  • $25,000,000Valuation cap

Purchased securities are not listed on any exchange. A secondary market for these securities does not currently exist and may never develop. You should not purchase these securities with the expectation that one eventually will.

Pops is offering securities under both Regulation CF and Regulation D through SI Securities, LLC ("SI Securities"). SI Securities is an affiliate of SeedInvest Technology, LLC, a registered broker-dealer, and member FINRA/SIPC. SI Securities will receive cash compensation equal to 7.50% of the value of the securities sold and equity compensation equal to 5.00% of the number of securities sold. Investments made under both Regulation CF and Regulation D involve a high degree of risk and those investors who cannot afford to lose their entire investment should not invest. Furthermore, this profile may contain forward-looking statements and information relating to, among other things, the company, its business plan and strategy, and its industry. Investors should review the risks and disclosures in the offering's draft. The contents of this profile are meant to be a summary of the information found in the company’s Form C. Before making an investment decision, investors should review the company’s Form C for a complete description of its business and offering information, a copy of which may be found both here and below.

Company Highlights

  • Revenue generating contracts are in place, including with key strategics such as Zurich Insurance Group, MOBE for Life, and Nice Healthcare
  • Achieved over a 90% average month-over-month user growth for the first four months of 2021
  • FDA-approved product with 15 issued patents and 16 pending patents
  • Clinical data accepted for ADA 2021 publication demonstrating a sustained and significant 15% improvement in A1c (glucose control), even after 18 months of Pops use
  • Key investors include Revolution ROTR, 30 Ventures, and Flying Point. Award winning (2016 American Diabetes Association, 2018 Inventures) and chosen as a 2018 Pepperdine Most Fundable company

Fundraise Highlights

  • Total Amount Raised: US $2,014,938
  • Total Round Size: US $3,000,000
  • Raise Description:  Series A
  • Minimum Investment:  US $1,000 per investor
  • Security Type:  Convertible Note
  • Valuation Cap:  US $25,000,000
  • Offering Type:   Side by Side Offering

Pops' mission is to define the future of virtual healthcare.  We enable people with chronic conditions to own their lives through technology.

Pops is focused on improving the current healthcare model. With diabetes as one of our most expensive chronic conditions in the world, we have not significantly changed how we manage diabetes in the last twenty-five years. Even the newest digital health companies continue to treat people with diabetes as patients to manage remotely with their live coaches. This model is lacking.

Pops has no live coaches and no traditional test kits. We don't see people as patients we need to manage. We see people who just want to live their life. Pops believes that if you give people a great enough consumer experience through a tech platform, they will choose to take care of their condition. This is a fundamental transformation in healthcare. A similar type of shift has already happened in other industries (e.g. for travel, people now book trips through their phone rather than via a travel agent).

Pops has developed an AI Virtual Health Assistant named Mina, who supports the user 24/7 in a non-judgmental way. We pair with Mina the Rebel meter, our simple method to measure blood sugar. This platform has FDA approval and is being sold in the U.S. Pops generated industry-unique clinical data that has been accepted for publication at the American Diabetes Association 2021 session demonstrating a significant glucose drop for 18 months of sustained use!

Pops is sold as a B2B2C subscription model. We used 2020 as a time to generate contracts with strategic partners and innovative health plans. We recently were one of the winners of the Zurich Innovation Challenge and are starting a paid sales pilot in Australia with Zurich. Zurich is an example of our focus on non-traditional health channels who are offering digital wellness.

With multiple contracts in place, Pops has demonstrated over a 90% month-over-month user growth on the platform in Q1 2021.

Pitch Deck

Media Mentions

The Team

Founders and Officers

Lonny Stormo

CEO and Chairman

Lonny worked at Medtronic for 30 years prior to co-founding Pops. During his Medtronic tenure, Lonny led a business unit and was in leadership roles in multiple functions across operations, engineering, clinical and quality.  

Lonny Stormo

CEO and Chairman

Lonny worked at Medtronic for 30 years prior to co-founding Pops. During his Medtronic tenure, Lonny led a business unit and was in leadership roles in multiple functions across operations, engineering, clinical and quality.  

Dan Davis


Dan spent 35 years in R&D and operations roles at 3M and multiple other companies. He has successfully introduced many new products in the healthcare field.  

Dan Davis


Dan spent 35 years in R&D and operations roles at 3M and multiple other companies. He has successfully introduced many new products in the healthcare field.  

Curt Christensen

VP Operations

Curt has spent more than 35 years in operations at 3M. He is an expert at processes, supply chain, and working with suppliers.

Curt Christensen

VP Operations

Curt has spent more than 35 years in operations at 3M. He is an expert at processes, supply chain, and working with suppliers.

Key Team Members

Nancy Phillips

VP Business Development

Nancy Ness


Stephanie Toomey

Customer Success Director

Notable Advisors & Investors

Revolution ROTR

Investor, Venture Investor

30 Ventures
Flying Point Industries
Dakota Ventures
John Brooks
Jeff Weness
Kim Mageau
Tom Tefft
George Arida
Elmer Baldwin
Warren Watson

Term Sheet

A Side by Side offering refers to a deal that is raising capital under two offering types. Investments made through the SeedInvest platform are offered via Regulation CF and subject to investment limitations further described in the Form C and/or subscription documents. Investments made outside of the SeedInvest platform are offered via Regulation D and requires one to be a verified accredited investor in order to be eligible to invest.

Fundraising Description

  • Round type:
    Series A

  • Round size:
    US $3,000,000

  • Raised to date:
    US $2,014,938
    US $126,800 (under Reg CF only)

  • Minimum investment:
    US $1,000

  • Target Minimum:
    US $300,000
  • Key Terms

  • Security Type:
    Convertible Note

  • Conversion discount:

  • Valuation Cap:
    US $25,000,000

  • Interest rate:

  • Note term:
    18 months
  • Additional Terms

  • Custody of Shares:

    Investors who invest less than $50,000 will have their securities held in trust with a Custodian that will serve as a single shareholder of record. These investors will be subject to the Custodian’s Account Agreement, including the electronic delivery of all required information. 

  • Total Amount Raised:

    The Total Amount Raised includes investments made outside of the SeedInvest platform, which may not be counting towards the escrow minimum. $1,888,138 has been raised prior to the launch of the SeedInvest campaign via Regulation D, of which, $1,486,138 is not being counted towards the escrow minimum. The earliest investment was made in September 2020. 

  • Closing conditions:
    While Pops has set an overall target minimum of US $300,000 for the round, Pops must raise at least US $25,000 of that amount through the Regulation CF portion of their raise before being able to conduct a close on any investments made via Regulation CF. For further information please refer to Pops's Form C.

  • Regulation CF cap:
    While Pops is offering up to US $3,000,000 worth of securities in its Series A, only up to US $1,070,000 of that amount may be raised through Regulation CF.

  • Transfer restrictions:
    Securities issued through Regulation CF have a one year restriction on transfer from the date of purchase (except to certain qualified parties as specified under Section 4(a)(6) of the Securities Act of 1933), after which they become freely transferable. While securities issued through Regulation D are similarly considered "restricted securities" and investors must hold their securities indefinitely unless they are registered with the SEC and qualified by state authorities, or an exemption from such registration and qualification requirements is available.

  • Use of Proceeds

    Investor Perks

    Bonus Perk: All Investors who invest $2,500 or more before Friday June 4, 2021 at 11:59pm ET, will receive a Pops Rebel welcome kit and registration code for the Mina app. Try out Pops yourself!

    Tier 1: Investors who invest $5,000 or more will be invited to our quarterly Mina's Studio event. The event includes notable guest speakers like our May 2021 guest, who has lived with diabetes since he was ten and is now biking across the United States to demonstrate that you can do anything with diabetes. 

    Tier 2: Investors who invest $10,000 or more will receive Tier 1 perks and will also be invited to Mina's Studio and an annual key investor webinar update.

    It is advised that you consult a tax professional to fully understand any potential tax implications of receiving investor perks before making an investment.

    Please note that due to share price calculations, some final investment amounts may be rounded down to the nearest whole share - these will still qualify for the designated perk tier. Additionally, investors must complete the online process and receive an initial email confirmation by the deadline stated above in order to be eligible for perks.

    Prior Rounds

    The graph below illustrates the valuation cap or the pre-money valuation of Pops's prior rounds by year.

    This chart does not represent guarantees of future valuation growth and/or declines.


  • Round Size
    US $500,000
  • Closed Date
    Feb 12, 2016
  • Security Type
    Convertible Note
  • Valuation Cap
    US $10,000,000
  • Series A

  • Round Size
    US $1,200,000
  • Closed Date
    Dec 15, 2016
  • Security Type
    Preferred Equity
  • Pre-Money valuation
    US $6,000,000
  • Series A-1

  • Round Size
    US $6,000,000
  • Closed Date
    Jun 28, 2019
  • Security Type
    Preferred Equity
  • Pre-Money valuation
    US $12,000,000
  • Market Landscape

    Digital Therapeutics for Diabetes Market Growth (North America)

    Pops competes in the Digital Health market for diabetes. The global Digital Health market size is growing at a 28% CAGR to $640B in 2026. The U.S. contributes the majority of this spending with 41% of Americans reporting use of Digital Health in their care. The category of Digital Health is large, so let’s further segment it down.

    Within Digital Health is the Digital Therapeutics category which is estimated to be $19B in 2028 at a 20% CAGR. About 25% of the $19B will be spent on diabetes. Today 34 million people in the U.S. have diabetes and it continues to grow by 4% per year. The total market size in 2028 for Pops’ market is then over $5B.

    The primary competitors in the diabetes Digital Therapeutics market are Livongo ($425M est. rev.), Omada ($125M est. rev.), Dario ($8M est. rev.), Onduo, and One Drop ($35M est. rev.). These are the competitors that Pops faces in its secondary target market of innovative health plans.

    However, Pops’ primary commercial target are large strategic partners who are beginning to offer digital wellness, especially if they are more consumer-wrapping solutions. Large corporations (e.g. Stanley Healthcare, Virgin Pulse) are entering the market due to its rapid growth and size. This is an opportunity for Pops. Pops’ platform can enable these companies to jumpstart digital therapeutics or be a diabetes tuck-in to their platform. Pops offers its platform solution as a service provider to these corporations looking to expand their consumer-health offerings.

    Pops has an advantage over the standalone “digital” competitors such as Livongo and Omada. They are offering traditional live coaching to remotely manage patients, along with traditional tools such as the glucose test kit. Pops has no live coaches, and offers Mina, a truly digital therapeutic, along with redesigned experiences like the Rebel meter.

    Risks and Disclosures

    The Total Amount Raised includes investments made outside of the SeedInvest platform via Regulation D, which may not be counting towards. the escrow minimum. $1,888,138 has been raised prior to the launch of the SeedInvest campaign via Regulation D, of which, $1,486,138 is not being counted towards the escrow minimum. The earliest investment was made in September 2020. There is no guarantee that the Company has this cash available for operations as of the date of launch.

    Noteholders may receive a less favorable conversion price due to granting of options or increases to the option pool in connection with the Qualified Financing. Future grants of options or common shares under any equity incentive plan of the Company,  as well as increases to the option pool in connection with the Qualified Financing are excluded from the calculation of a conversion price, which may lead to noteholders receiving a less favorable conversion price.

    The development and commercialization of the Company’s products and services are highly competitive. It faces competition with respect to any products and services that it may seek to develop or commercialize in the future. Its competitors include major companies worldwide. The personal care market is an emerging industry where new competitors are entering the market frequently. Many of the Company’s competitors have significantly greater financial, technical and human resources and may have superior expertise in research and development and marketing approved services and thus may be better equipped than the Company to develop and commercialize services. These competitors also compete with the Company in recruiting and retaining qualified personnel and acquiring technologies. Smaller or early stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Accordingly, the Company’s competitors may commercialize products more rapidly or effectively than the Company is able to, which would adversely affect its competitive position, the likelihood that its services will achieve initial market acceptance and its ability to generate meaningful additional revenues from its products and services.

    Manufacturing or design defects, unanticipated use of the Company's products, or inadequate disclosure of risks relating to the use of the products could lead to injury or other adverse events. These events could lead to recalls or safety alerts relating to its products (either voluntary or required by governmental authorities) and could result, in certain cases, in the removal of a product from the market. Any recall could result in significant costs as well as negative publicity that could reduce demand for its products. Personal injuries relating to the use of its products could also result in product liability claims being brought against the Company. In some circumstances, such adverse events could also cause delays in new product approvals. Similarly, negligence in performing its services can lead to injury or other adverse events.

    A product recall or an adverse result in litigation could have an adverse effect on the Company's business. The adverse effect depends on the costs of the recall, the destruction of product inventory, competitive reaction, and consumer attitudes. Even if a product liability claim is unsuccessful or without merit, the negative publicity surrounding such assertions could adversely affect their reputation and brand image. The Company also could be adversely affected if consumers in their principal markets lose confidence in the safety and quality of their products.

    Maintaining, extending, and expanding the Company's reputation and brand image are essential to the Company's business success. The Company seeks to maintain, extend, and expand their brand image through marketing investments, including advertising and consumer promotions, and product innovation. Increasing attention on marketing could adversely affect the Company's brand image. It could also lead to stricter regulations and greater scrutiny of marketing practices. Existing or increased legal or regulatory restrictions on the Company's advertising, consumer promotions and marketing, or their response to those restrictions, could limit their efforts to maintain, extend and expand their brands. Moreover, adverse publicity about regulatory or legal action against the Company could damage the Company's reputation and brand image, undermine their customers’ confidence and reduce long-term demand for their products, even if the regulatory or legal action is unfounded or not material to their operations.

    In addition, the Company's success in maintaining, extending, and expanding the Company's brand image depends on their ability to adapt to a rapidly changing media environment. The Company increasingly relies on social media and online dissemination of advertising campaigns. The growing use of social and digital media increases the speed and extent that information or misinformation and opinions can be shared. Negative posts or comments about the Company, their brands or their products on social or digital media, whether or not valid, could seriously damage their brand and reputation. If the Company does not establish, maintain, extend and expand their brand image, then their product sales, financial condition and results of operations could be adversely affected.

    The Company may be unable to maintain, promote, and grow its brand through marketing and communications strategies. It may prove difficult for the Company to dramatically increase the number of customers that it serves or to establish itself as a well-known brand. Additionally, the product may be in a market where customers will not have brand loyalty.

    The Company conducts business in a heavily regulated industry. If it fails to comply with these laws and government regulations, it could incur penalties or be required to make significant changes to its operations or experience adverse publicity, which could have a material adverse effect on its business, financial condition, and results of operations. The healthcare industry is heavily regulated and closely scrutinized by federal, state, and local governments. Comprehensive statutes and regulations govern the manner in which the Company provides and bills for services and collects reimbursement from governmental programs and private payers, contractual relationships with Providers, vendors and Clients, marketing activities, and other aspects of its operations. Because of the breadth of these laws and the narrowness of the statutory exceptions and safe harbors available, it is possible that some of the Company’s business activities could be subject to challenge under one or more of such laws. Achieving and sustaining compliance with these laws may prove costly. Failure to comply with these laws and other laws can result in civil and criminal penalties such as fines, damages, overpayment recoupment loss of enrollment status, and exclusion from the government programs. The risk of the Company being found in violation of these laws and regulations is increased by the fact that many of them have not been fully interpreted by the regulatory authorities or the courts, and their provisions are sometimes open to a variety of interpretations. The Company’s failure to accurately anticipate the application of these laws and regulations to the business or any other failure to comply with regulatory requirements could create liability and negatively affect the business. Any action against the Company for violation of these laws or regulations, even if they successfully defend against it, could cause them to incur significant legal expenses, divert management's attention from the operation of the business, and result in adverse publicity.

    Quality management plays an essential role in determining and meeting customer requirements, preventing defects, improving the Company’s products and services, and maintaining the integrity of the data that supports the safety and efficacy of its products. The Company's future success depends on their ability to maintain and continuously improve their quality management program. An inability to address a quality or safety issue in an effective and timely manner may also cause negative publicity, a loss of customer confidence in the Company or the Company's current or future products, which may result in the loss of sales and difficulty in successfully launching new products. In addition, a successful claim brought against the Company in excess of available insurance or not covered by indemnification agreements, or any claim that results in significant adverse publicity against the Company could have an adverse effect on their business and their reputation.

    The Company’s expenses will significantly increase as they seek to execute their current business model. Although the Company estimates that it has enough cash and inventory runway for the rest of the year, they will be ramping up cash burn to promote revenue growth, further develop R&D, and fund other Company operations after the raise. Doing so could require significant effort and expense or may not be feasible.

    The Company’s business model is capital intensive. The amount of capital the Company is attempting to raise in this Offering is not enough to sustain the Company’s current business plan. In order to achieve near and long-term goals, the Company will need to procure funds in addition to the amount raised in the Offering. There is no guarantee the Company will be able to raise such funds on acceptable terms or at all. If the Company is not able to raise sufficient capital in the future, then it will not be able to execute its business plan, its continued operations will be in jeopardy and it may be forced to cease operations and sell or otherwise transfer all or substantially all of its remaining assets, which could cause a Purchaser to lose all or a portion of his or her investment.

    The Company projects aggressive growth. If these assumptions are wrong and the projections regarding market penetration are too aggressive, then the financial forecast may overstate the Company's overall viability. In addition, the forward-looking statements are only predictions. The Company has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements.

    The Company has outstanding debt. The Company approximately owes $188,400 to the Minnesota Department of Employment & Economic Development (DEED) for an Angel Loan Fund Program loan. This loan was granted in October of 2017 and is not due for 84 months from the granting date. The loan does not accrue any interest until  the end of the term.

    The Company has participated in Related Party Transactions. In 2018, the Company issued an unsecured convertible note totaling $125,000 to a related party which is due in January 2020 and was still in outstanding as of December 31, 2020. The note accrued interest at 8 percent and is automatically convertible into shares issued in connection with qualified financing at a conversion price equal to 100 percent of the price paid by investors in such financing. As of December 31, 2020, there was $31,841 of accrued interest included in the accrued expenses.

    The Company has outstanding Convertible Debt.  The Company has outstanding Convertible Notes worth approximately $1.5M of principal. The convertible notes are convertible into Series A Preferred Stock at a conversion price on April 15, 2022 (the ‘Maturity date’). The conversion price is equal to the lesser of (a) 80% of the price paid per share for Equity Securities by the investor in the Qualified Financing (gross proceed of at least $ 4,000,000) and (b) the price equal to the quotient resulting from dividing $25,000,0000 by the number of outstanding shares of common stock of the company immediately prior the Qualified Financing. Since the conversion feature is convertible into variable number of shares and does not have fixed-for-fixed features, the conversion feature was not bifurcated and recorded separately.

    The reviewing CPA has included a “going concern” note in the reviewed financials. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company's current situation raises a doubt on whether the entity can continue as a going concern in the next twelve months, and its ability to continue is dependent upon its ability to produce revenues and/or obtain financing sufficient to meet current and future obligations and deploy such to produce profitable operating results. Management has evaluated these conditions and plans to generate revenues and raise capital as needed to satisfy its capital needs. During the next twelve months, the Company intends to fund its operations through debt and/or equity financing. There are no assurances that management will be able to raise capital on terms acceptable to the Company. If it is unable to obtain sufficient amounts of additional capital, it may be required to reduce the scope of its planned development, which could harm its business, financial condition, and operating results. The accompanying financial statements do not include any adjustments that might result from these uncertainties.

    The Company has not yet prepared audited financial statements for 2020. The Company undergoes periodic Audits for each year of operation, although this Audit for 2020 is not yet complete. Therefore, investors have no audited financial information regarding the Company’s capitalization or assets or liabilities for 2020 on which to make investment decisions. If investors feel the information provided is insufficient, then they should not invest in the Company.

    The outbreak of the novel coronavirus, COVID-19, has adversely impacted global commercial activity and contributed to significant declines and volatility in financial markets. The coronavirus pandemic and government responses are creating disruption in global supply chains and adversely impacting many industries. The outbreak could have a continued material adverse impact on economic and market conditions and trigger a period of global economic slowdown. The rapid development and fluidity of this situation precludes any prediction as to the ultimate material adverse impact of the novel coronavirus. Nevertheless, the novel coronavirus presents material uncertainty and risk with respect to the Funds, their performance, and their financial results.

    General Risks and Disclosures

    Start-up investing is risky. Investing in startups is very risky, highly speculative, and should not be made by anyone who cannot afford to lose their entire investment. Unlike an investment in a mature business where there is a track record of revenue and income, the success of a startup or early-stage venture often relies on the development of a new product or service that may or may not find a market. Before investing, you should carefully consider the specific risks and disclosures related to both this offering type and the company which can be found in this company profile and the documents in the data room below.

    Your shares are not easily transferable. You should not plan on being able to readily transfer and/or resell your security. Currently there is no market or liquidity for theseshares and the company does not have any plans to list these shares on an exchange or other secondary market. At some point the company may choose to do so, but until then you should plan to hold your investment for a significant period of time before a "liquidation event" occurs. A "liquidation event" is when the company either lists their shares on an exchange, is acquired, or goes bankrupt.

    The Company may not pay dividends for the foreseeable future. Unless otherwise specified in the offering documents and subject to state law, you are not entitled to receive any dividends on your interest in the Company. Accordingly, any potential investor who anticipates the need for current dividends or income from an investment should not purchase any of the securities offered on the Site.

    Valuation and capitalization. Unlike listed companies that are valued publicly through market-driven stock prices, the valuation of private companies, especially startups, is difficult to assess and you may risk overpaying for your investment. In addition, there may be additional classes of equity with rights that are superior to the class of equity being sold.

    You may only receive limited disclosure. While the company must disclose certain information, since the company is at an early-stage they may only be able to provide limited information about its business plan and operations because it does not have fully developed operations or a long history. The company may also only obligated to file information periodically regarding its business, including financial statements. A publicly listed company, in contrast, is required to file annual and quarterly reports and promptly disclose certain events \u2014 through continuing disclosure that you can use to evaluate the status of your investment.

    Investment in personnel. An early-stage investment is also an investment in the entrepreneur or management of the company. Being able to execute on the business plan is often an important factor in whether the business is viable and successful. You should be aware that a portion of your investment may fund the compensation of the company's employees, including its management. You should carefully review any disclosure regarding the company's use of proceeds.

    Possibility of fraud. In light of the relative ease with which early-stage companies can raise funds, it may be the case that certain opportunities turn out to be money-losing fraudulent schemes. As with other investments, there is no guarantee that investments will be immune from fraud.

    Lack of professional guidance. Many successful companies partially attribute their early success to the guidance of professional early-stage investors (e.g., angel investors and venture capital firms). These investors often negotiate for seats on the company's board of directors and play an important role through their resources, contacts and experience in assisting early-stage companies in executing on their business plans. An early-stage company may not have the benefit of such professional investors.

    Pops's Form C

    The Form C is a document the company must file with the Securities and Exchange Commission, which includes basic information about the company and its offering and is a condition to making a Reg CF offering available to investors. It is important to note that the SEC does not review the Form C, and therefore is not recommending and/or approving any of the securities being offered.

    Download Pops's  Form C

    Frequently Asked Questions

    About Side by Side Offerings
    What is Side by Side?

    A Side by Side offering refers to a deal that is raising capital under two offering types. This Side by Side offering is raising under Regulation CF and Rule 506(c) of Regulation D.

    What is a Form C?

    The Form C is a document the company must file with the Securities and Exchange Commission (“SEC”) which includes basic information about the company and its offering and is a condition to making a Reg CF offering available to investors. It is important to note that the SEC does not review the Form C, and therefore is not recommending and/or approving any of the securities being offered.

    Before making any investment decision, it is highly recommended that prospective investors review the Form C filed with the SEC (included in the company's profile) before making any investment decision.

    What is Rule 506(c) under Regulation D?

    Rule 506(c) under Regulation D is a type of offering with no limits on how much a company may raise. The company may generally solicit their offering, but the company must verify each investor’s status as an accredited investor prior to closing and accepting funds. To learn more about Rule 506(c) under Regulation D and other offering types check out our blog and academy.

    What is Reg CF?

    Title III of the JOBS Act outlines Reg CF, a type of offering allowing private companies to raise up to $5 million from all Americans. Prior capital raising options limited private companies to raising money only from accredited investors, historically the wealthiest ~2% of Americans. Like a Kickstarter campaign, Reg CF allows companies to raise funds online from their early adopters and the crowd. However, instead of providing investors a reward such as a t-shirt or a card, investors receive securities, typically equity, in the startups they back. To learn more about Reg CF and other offering types check out our blog and academy.

    Making an Investment in Pops
    How does investing work?

    When you complete your investment on SeedInvest, your money will be transferred to an escrow account where an independent escrow agent will watch over your investment until it is accepted by Pops. Once Pops accepts your investment, and certain regulatory procedures are completed, your money will be transferred from the escrow account to Pops in exchange for your securities. At that point, you will be a proud owner in Pops.

    What will I need to complete my investment?

    To make an investment, you will need the following information readily available:

    1. Personal information such as your current address and phone number
    2. Employment and employer information
    3. Net worth and income information
    4. Your accredited investor status
    5. Social Security Number or passport
    6. ABA bank routing number and checking account number (typically found on a personal check or bank statement) or debit card information, unless paying via a Wire transfer.

    How much can I invest?

    Non-accredited investors are limited in the amount that he or she may invest in a Reg CF offering during any rolling 12-month period:

    • If either the annual income or the net worth of the investor is less than $107,000, the investor is limited to the greater of $2,200 or 5% of the greater of his or her annual income or net worth.
    • If the annual income and net worth of the investor are both greater than $107,000, the investor is limited to 10% of the greater of his or her annual income or net worth, to a maximum of $107,000.

    Separately, Pops has set a minimum investment amount of US $1,000.

    Accredited investors do not have any investment limits.

    After My Investment
    What is my ongoing relationship with the Issuer?

    You are a partial owner of the company, you do own securities after all! But more importantly, companies which have raised money via Regulation CF must file information with the SEC and post it on their websites on an annual basis. Receiving regular company updates is important to keep shareholders educated and informed about the progress of the company and their investment. This annual report includes information similar to a company’s initial Reg CF filing and key information that a company will want to share with its investors to foster a dynamic and healthy relationship.

    In certain circumstances a company may terminate its ongoing reporting requirement if:

    1. The company becomes a fully-reporting registrant with the SEC
    2. The company has filed at least one annual report, but has no more than 300 shareholders of record
    3. The company has filed at least three annual reports, and has no more than $10 million in assets
    4. The company or another party purchases or repurchases all the securities sold in reliance on Section 4(a)(6)
    5. The company ceases to do business

    However, regardless of whether a company has terminated its ongoing reporting requirement per SEC rules, SeedInvest works with all companies on its platform to ensure that investors are provided quarterly updates. These quarterly reports will include information such as: (i) quarterly net sales, (ii) quarterly change in cash and cash on hand, (iii) material updates on the business, (iv) fundraising updates (any plans for next round, current round status, etc.), and (v) any notable press and news.

    How can I sell my securities in the future?

    Currently there is no market or liquidity for these securities. Right now Pops does not plan to list these securities on a national exchange or another secondary market. At some point Pops may choose to do so, but until then you should plan to hold your investment for a significant period of time before a “liquidation event” occurs. A “liquidation event” is when Pops either lists their securities on an exchange, is acquired, or goes bankrupt.

    How do I keep track of this investment?

    You can return to SeedInvest at any time to view your portfolio of investments and obtain a summary statement. If invested under Regulation CF you may also receive periodic updates from the company about their business, in addition to monthly account statements.

    Other General Questions
    What is this page about?

    This is Pops's fundraising profile page, where you can find information that may be helpful for you to make an investment decision in their company. The information on this page includes the company overview, team bios, and the risks and disclosures related to this investment opportunity. If the company runs a side by side offering that includes an offering under Regulation CF, you may also find a copy of the Pops's Form C. The Form C includes important details about Pops's fundraise that you should review before investing.

    How can I (or the company) cancel my investment under Regulation CF?

    For offerings made under Regulation CF, you may cancel your investment at any time up to 48 hours prior to the offering end date or an earlier date set by the company. You will be sent a notification at least five business days prior to a closing that is set to occur earlier than the original stated end date giving you an opportunity to cancel your investment if you have not already done so. Once a closing occurs, and if you have not canceled your investment, you will receive an email notifying you that your securities have been issued. If you have already funded your investment, your funds will be promptly refunded to you upon cancellation. To cancel your investment, you may go to your account's portfolio page by clicking your profile icon in the top right corner.

    What if I change my mind about investing?

    If you invest under any other offering type, you may cancel your investment at any time, for any reason until a closing occurs. You will receive an email when the closing occurs and your securities have been issued. If you have already funded your investment and your funds are in escrow, your funds will be promptly refunded to you upon cancellation. To cancel your investment, please go to your account's portfolio page by clicking your profile icon in the top right corner.